Markets

Baxter (BAX) Receives FDA Clearance for AMIA APD System

Baxter International Inc.BAX recently announced that the FDA has approved its AMIA automated peritoneal dialysis (APD) system with the SHARESOURCE web-based remote connectivity platform.

Peritoneal dialysis is a medical procedure to remove waste products from a patient's blood when the kidneys are not entirely functional.

Baxter joined forces with DEKA Research and Development Corporation (DEKA) to develop the AMIA APD system, which offers peritoneal dialysis for patients suffering from end-stage renal disease (ESRD). Baxter expects to roll out the product this year.

Notably, AMIA APD system is the only FDA approved product in the U.S. that possesses patient-friendly features such as voice guidance, a touchscreen control panel and the SHARESOURCE two-way connectivity platform.

With the help of the SHARESOURCE platform, physicians will be able to efficiently access the past treatment data of home patients and provide individual prescriptions remotely.

AMIA APD system comes with sophisticated, animated graphics and automatic step-by-step commands, which is built to increase the effectiveness of home therapy guidance and management for ESRD patients.

Reportedly, more than 600,000 individuals are currently suffering from ESRD and are in dire need of peritoneal dialysis. According to a report by market research firm MarketsandMarkets, the global peritoneal dialysis market is expected to reach a worth of approximately $83.21 billion by 2018. The favorable market trend thus presents significant growth opportunities for Baxter.

However, the peritoneal dialysis market is rife with competition with players like Fresenius Medical Care AG & Co. KGAA FMS and Nxstage Medical NXTM .

Zacks Rank and Another Key Pick

Currently, Baxter has a Zacks Rank #1 (Strong Buy). Another well-placed stock in the Medical Products industry is NuVasive NUVA , with a Zacks Rank #1.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

BAXTER INTL (BAX): Free Stock Analysis Report

FRESENIUS MED (FMS): Free Stock Analysis Report

NUVASIVE INC (NUVA): Free Stock Analysis Report

NXSTAGE MEDICAL (NXTM): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

NUVA BAX FMS

Other Topics

Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More